Nuvalent

Acquired

Nuvalent is a biotech company in Cambridge, United States, founded in 2017. It has raised $185.0M across 3 rounds, most recently a $135.0M Series B in May 2021.

Precisely targeted therapies for patients with cancer

Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$185.0M
Last Round
$135.0M Series BMay 2021
Rounds
3
Type
Public
Acquisition Date
Jun 2026

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 4 investors for this company. The full record is or through the API.

About

Nuvalent is a clinical-stage biopharmaceutical company advancing precisely targeted therapies for cancer using structure-based drug discovery and small molecule chemistry. Its pipeline focuses on kinase inhibitors zidesamtinib (NVL-520) for ROS1-positive NSCLC and neladalkib (NVL-655) for ALK-positive NSCLC, with NVL-330 targeting HER2-altered NSCLC. GSK entered an agreement to acquire Nuvalent in June 2026.

Summary

It lists 51–200 employees. It has raised $185.0M in total across 3 rounds, most recently a $135.0M Series B round in May 2021. Investors include Deerfield Management, GSK and Wellington Management.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionJun 2026

Sign up to see all 5 events

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nuvalent on Indexed.vc
<a href="https://indexed.vc/companies/nuvalent"><img src="https://indexed.vc/api/badge/company/nuvalent" alt="Nuvalent on Indexed.vc" width="260" height="76" /></a>